Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Menne

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Journal of the American College of Cardiology|October 2, 2010
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility studyIngrid J M Scheffers, Abraham A Kroon, Jürg Schmidli, et al.
Neurology|September 21, 2012
Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adultsKarin Weissenborn, Frank Donnerstag, Jan T Kielstein, et al.
Blood|June 5, 2024
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeLucas Kühne, Paul Knöbl, Kathrin Eller, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2014
Eligibility for renal denervation: experience at 11 European expert centersAlexandre Persu, Yu Jin, Marie Baelen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2024
Interactive exploration of adverse events and multimorbidity in CKDInga Steinbrenner, Fruzsina Kotsis, Robin Kosch, et al.
Journal of the American Society of Nephrology : JASN|January 16, 2015
Diagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesJoost P Schanstra, Petra Zürbig, Alaa Alkhalaf, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
JAMA|June 4, 2026
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical TrialSunil V Badve, Vlado Perkovic, Vivekanand Jha, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Journal of the American College of Cardiology|October 2, 2010
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility studyIngrid J M Scheffers, Abraham A Kroon, Jürg Schmidli, et al.
Neurology|September 21, 2012
Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adultsKarin Weissenborn, Frank Donnerstag, Jan T Kielstein, et al.
Blood|June 5, 2024
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeLucas Kühne, Paul Knöbl, Kathrin Eller, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2014
Eligibility for renal denervation: experience at 11 European expert centersAlexandre Persu, Yu Jin, Marie Baelen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2024
Interactive exploration of adverse events and multimorbidity in CKDInga Steinbrenner, Fruzsina Kotsis, Robin Kosch, et al.
Journal of the American Society of Nephrology : JASN|January 16, 2015
Diagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesJoost P Schanstra, Petra Zürbig, Alaa Alkhalaf, et al.
American Journal of Nephrology|February 9, 2026
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) TrialSunil V Badve, Maha Al Ammari, Craig S Anderson, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
JAMA|June 4, 2026
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical TrialSunil V Badve, Vlado Perkovic, Vivekanand Jha, et al.
Pageof 12